P3 Health Partners (PIII) AI Stock Analysis

• Market Cap: $60.81M
• Dividend Yield: N/A
• Average Volume (3M): 7.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: -2.15%
• EPS Growth: -6.72%
• Country: US
• Employees: 360
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -9.67
• Shares Outstanding: 3,268,218
• 10 Day Avg. Volume: 4,406
• 30 Day Avg. Volume: 7,400
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.02
• P/FCF Ratio: -0.30
• Enterprise Value/Market Cap: 3.56
• Enterprise Value/Revenue: 0.15
• Enterprise Value/Gross Profit: 0.31
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: $10.25
• Price Target Upside: 72.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $5.50 ▼(-7.41% Downside)

P3 Health Partners faces significant financial challenges, with high leverage and negative profitability metrics. Technical indicators suggest bearish momentum, and the valuation is unattractive due to ongoing losses. While the earnings call provided some positive insights, the financial risks remain predominant.

Positive Factors

Revenue Growth

The increase in capitated revenue indicates effective clinical programs and utilization management, supporting long-term revenue growth.

Operational Improvements

Significant EBITDA improvement suggests successful operational strategies, enhancing long-term financial performance.

Strategic Joint Venture

The joint venture expands member base, potentially boosting profitability and cash flow, strengthening market position.

Negative Factors

Profitability Challenges

Ongoing EBITDA losses highlight persistent profitability issues, which could hinder long-term financial stability.

High Leverage

High leverage indicates financial risk and limits flexibility, potentially impacting the company's ability to invest in growth.

Negative Cash Flow

Negative cash flow suggests operational inefficiencies, which could strain resources and affect long-term sustainability.

P3 Health Partners Business Overview & Revenue Model

Company Description

P3 Health Partners (PIII) is a healthcare organization focused on providing value-based care solutions and enhancing patient outcomes through innovative healthcare management. Operating primarily in the healthcare sector, PIII partners with Medicare Advantage plans and other payers to deliver comprehensive care management services. The company's core offerings include population health management, care coordination, and analytics-driven solutions designed to improve care delivery and reduce overall healthcare costs for patients and providers alike.

How the Company Makes Money

P3 Health Partners generates revenue primarily through capitation payments and performance-based incentives from Medicare Advantage plans and other payers. Under the capitation model, PIII receives a fixed amount per enrolled member to provide a range of healthcare services, allowing the company to manage costs effectively while focusing on preventive care and patient management. Additionally, P3 may earn bonuses for meeting specific quality metrics and improving patient outcomes, which further contributes to its revenue streams. Strategic partnerships with healthcare providers and payers enhance its service offerings and market reach, playing a significant role in its financial success.

P3 Health Partners Financial Statement Overview

Summary

P3 Health Partners is experiencing revenue growth but struggles with profitability and financial stability. High leverage and negative margins pose significant risks, and the company needs to focus on improving operational efficiency and reducing debt to strengthen its financial position.

Income Statement

P3 Health Partners has shown a notable revenue growth from the previous year, with a 18.48% increase in 2024. Despite this, the company struggles with profitability, evidenced by negative gross profit margins and a significant net loss. EBIT and EBITDA margins are also negative, indicating challenges in covering operational costs and interest expenses.

Balance Sheet

The balance sheet reflects high leverage with a debt-to-equity ratio standing at 1.01, indicating potential risk in financial stability. The equity ratio is low at 9.69%, suggesting limited buffer against liabilities. Return on equity is highly negative, reflecting the net losses impacting shareholder value.

Cash Flow

The cash flow statement reveals negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting profits into cash. However, there's a positive cash inflow from financing activities which may provide temporary relief.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.44B	1.50B	1.27B	1.05B	637.36M	491.06M
Gross Profit	696.16M	1.50B	1.27B	1.05B	-30.70M	491.06M
EBITDA	-147.95M	-197.76M	-81.07M	-1.46B	-184.61M	-28.08M
Net Income	-131.05M	-135.85M	-57.77M	-270.13M	-156.48M	-31.41M
Balance Sheet
Total Assets	683.56M	783.42M	860.97M	876.74M	2.36B	106.44M
Cash, Cash Equivalents and Short-Term Investments	37.71M	38.82M	36.32M	18.46M	140.48M	36.26M
Total Debt	50.66M	166.16M	124.64M	107.54M	92.02M	51.29M
Total Liabilities	664.64M	633.89M	427.31M	354.08M	299.94M	236.65M
Stockholders Equity	-18.69M	75.94M	142.13M	5.85M	273.55M	-130.22M
Cash Flow
Free Cash Flow	-122.87M	-110.13M	-77.86M	-128.25M	-69.88M	-27.52M
Operating Cash Flow	-122.75M	-110.13M	-76.03M	-126.02M	-66.47M	-24.60M
Investing Cash Flow	-544.00K	14.53M	-1.83M	-7.73M	-56.07M	-3.17M
Financing Cash Flow	93.66M	98.77M	100.33M	11.38M	223.47M	34.76M

P3 Health Partners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PIII, the sentiment is Negative. The current price of 5.94 is below the 20-day moving average (MA) of 7.46, below the 50-day MA of 8.32, and below the 200-day MA of 8.09, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 28.73 is Positive, neither overbought nor oversold. The STOCH value of 9.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PIII.

P3 Health Partners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PNTG	68 Neutral	$927.11M	35.43	10.87%	―	29.89%	10.33%
INNV	57 Neutral	$656.49M	-21.62	-6.86%	―	12.48%	-9.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TOI	47 Neutral	$299.08M	―	-3407.86%	―	21.67%	16.74%
DCGO	45 Neutral	$99.77M	―	-17.32%	―	-47.03%	-274.41%
AGL	41 Neutral	$265.83M	―	-73.31%	―	5.21%	5.21%
PIII	38 Underperform	$60.81M	-0.17	-257.39%	―	-2.15%	-6.72%

P3 Health Partners Corporate Events

P3 Health Partners Earnings Call Reveals Growth Amid Challenges

P3 Health Partners Inc. recently held its earnings call, revealing a mix of positive developments and ongoing financial challenges. The company reported increased capitated revenue, successful operational improvements, strategic ventures, and reduced operating expenses. However, these achievements were tempered by significant adjusted EBITDA losses and revised financial guidance, indicating that financial hurdles remain.

P3 Health Partners Reports Q3 2025 Financial Results

P3 Health Partners Inc. is a patient-centered and physician-led population health management company that focuses on improving healthcare outcomes through value-based care coordination and administrative services. The company operates in the healthcare sector, managing the care of thousands of patients across four states in the United States.

P3 Health Partners Forms New MSO with Commonwealth

On November 11, 2025, P3 Health Partners REACH ACO, LLC entered into an agreement with Commonwealth Primary Care ACO, LLC to form P3 Commonwealth Innovation MSO, LLC. This new entity will manage and coordinate activities for ACOs, focusing on shared services, financial management, and clinical integration. The MSO will receive management fees and a portion of net shared savings from the ACOs, with P3 ACO holding an 80% membership interest. The formation of this MSO is expected to enhance the operational efficiency and quality of care provided by the involved ACOs.

The most recent analyst rating on (PIII) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on P3 Health Partners stock, see the PIII Stock Forecast page.

P3 Health Partners Earnings Call: Challenges and Progress

P3 Health Partners Inc. Earnings Call: Navigating Challenges and Progress

P3 Health Partners Extends Term Loan Agreement

On August 27, 2025, P3 Health Group, LLC, a subsidiary of P3 Health Partners Inc., entered into the Tenth Amendment to its Term Loan Agreement originally dated November 19, 2020. The amendment extends the interest-only period to September 30, 2026, and the maturity date to December 31, 2027, while adjusting the principal payments and interest rates. These changes aim to provide financial flexibility and stability for the company, potentially impacting its operational capabilities and stakeholder interests.

The most recent analyst rating on (PIII) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on P3 Health Partners stock, see the PIII Stock Forecast page.